Kantaro Biosciences, a joint venture between the Mount Sinai Health System and RenalytixAI (RNLX), has received Emergency Use Authorization from the FDA for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test kit. COVID-SeroKlir has showed 98.8% sensitivity and 99.6% specificity for detecting SARS-CoV-2 specific IgG antibodies against two virus antigens. Kantaro noted that, unlike other antibody tests, COVID-SeroKlir determines the presence and precise level of IgG antibodies.
Through a commercial partnership with Bio-Techne Corp. (TECH), the test kits are being manufactured at scale with a capacity of up to 10 million tests per month.
For comments and feedback contact: editorial@rttnews.com
Business News
January 30, 2026 15:51 ET The Federal Reserve policy decision was the main event in the final week of January, which saw a heavy flow of economics news. Several data reflecting the trends in the U.S. economy were also released during the week. The interest rate decision from Canada also was in focus. In Europe, economic sentiment data gained attention. The policy decision from Singapore was the highlight in Asia.